Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Subscribe To Our Newsletter & Stay Updated